Albany Molecular Research (AMRI) Stock Plummets on Weak Earnings, Guidance

NEW YORK (TheStreet) -- Shares of Albany Molecular Research  (AMRI) plummeted 22.58% to $17.55 in afternoon trading Wednesday after the company reported third-quarter earnings that came up well short of analysts' expectations.

The company, which provides global contract research and manufacturing services to the pharmaceutical and biotechnology industries, reported a loss of $8.6 million, or 27 cents a share, for the quarter. The adjusted loss came to 2 cents a share. Revenue totaled $62.5 million for the period.

Analysts had expected adjusted earnings of 16 cents a share on revenue of $71 million.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

For the full year, Albany Molecular Research expects earnings in the range of 67 cents to 73 cents on revenue in the range of $278 million to $286 million. The consensus estimate calls for earnings of 88 cents a share on revenue of $304.31 million.

More than 3 million shares had changed hands as of 12:48 p.m., compared to the average volume of 311,765.

AMRI Chart AMRI data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Video: Jim Cramer on Rising Interest Rates, Trade Worries & Caterpillar

Stocks Trade Lower as 10-Year Yield Hits 3%

Stocks Trade Lower as 10-Year Yield Hits 3%

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns